Epstein Barr Virus Antibody Panel
Test Codes
EPIC: LAB1231655, SOFT: EBVP, Antrim #30931
Department
Immunology
Specimen Collection Criteria
Collect: One Gold-top SST tube. (Minimum Whole Blood: 2.0 mL)
Physician Office/Draw Specimen Preparation
Let specimen clot 30-60 minutes then immediately centrifuge to separate serum from cells. Refrigerate (2-8°C or 36-46°F) the centrifuged collection tube within twelve hours of collection. (Minimum: 0.5 mL)
Preparation for Courier Transport
Transport: Centrifuged collection tube, refrigerated (2-8°C or 36-46°F). (Minimum: 0.5 mL)
Rejection Criteria
- Plasma specimens.
- Severely lipemic, icteric, or grossly hemolyzed specimens.
In-Lab Processing
Let specimen clot 30-60 minutes then immediately centrifuge to separate serum from cells. Room temperature is acceptable for a maximum of twelve hours. (Minimum: 0.5 mL)
Storage
Specimen Stability for Testing:
Centrifuged SST Tubes, Red-top Tubes, and Microtainers®
Room Temperature (20-26°C or 68-78.8°F): 12 hours
Refrigerated (2-8°C or 36-46°F): 7 days
Frozen (-20°C/-4°F or below): Unacceptable
Serum Specimens (Pour-Overs)
Room Temperature (20-26°C or 68-78.8°F): 12 hours
Refrigerated (2-8°C or 36-46°F): 7 days
Frozen (-20°C/-4°F or below): 3 months
Specimen Storage in Department Prior to Disposal:
Refrigerated (2-8°C or 36-46°F): 7 days
Laboratory
Royal Oak Special Testing Laboratory
Performed
Monday – Friday.
Results available within two business days.
Reference Range
EBV-VCA IgG: Negative
EBV-VCA IgM: Negative
EBNA IgG: Negative
EBV-EA IgG: Negative
Test Methodology
Indirect Chemiluminescent Immunoassay (CLIA).
Interpretation
EBV Panel Interpretation:
Condition |
VCA IgG |
VCA IgM |
EBNA IgG |
EBV seronegative |
negative |
negative |
negative |
Acute infection |
positive |
positive |
negative |
Past infection |
positive |
negative |
positive |
Indeterminate |
VCA IgG only |
positive |
negative |
negative |
VCA IgM only |
negative |
positive |
negative |
EBNA IgG only |
negative |
negative |
positive |
Convalescent |
positive |
positive |
positive |
Interpretation |
VCA IgG |
VCA IgM |
EBNA |
EA IgG
|
Susceptible |
negative |
negative |
negative |
negative |
Acute primary infection |
negative |
positive |
negative |
positive |
Late primary infection |
positive |
positive |
positive |
positive |
Past infection |
positive |
negative |
positive |
negative |
EBV Reactivation |
positive |
negative |
positive |
positive |
The above table contains the most frequently observed serological patterns. These patterns may be helpful when correlated with the clinical presentation.
Some children will appear to be seronegative except for EBNA IgG or EBV-EA IgG. This serological pattern is suggestive of an exposure to a cross-reacting antigen.
Clinical Utility
Epstein-Barr virus (EBV) is difficult to diagnose using one serological assay. Diagnosis of an acute or recurrent infection is best accomplished by using a panel of assays including: concurrent EBV VCA-IgG, EBV VCA-IgM, EBNA IgG, and Early Antigen tests.
Clinical Disease
Epstein-Barr virus (EBV) is the etiological agent of infectious mononucleosis and has been implicated in African Burkitt's lymphoma and nasopharyngeal carcinoma.
Childhood infections may be asymptomatic or produce "flu-like" illness. Adolescents and adults who escape infection during childhood experience infectious mononucleosis (IM). IM is characterized by irregular fever, pharyngitis, and lymphadenopathy lasting 1 to 4 weeks. Hematological abnormalities include an absolute increase in lymphocytes and monocytes exceeding 50% and more than 15% atypical lymphocytes, lasting for at least 2 weeks. Liver function tests generally reveal a mild to moderate increase in SPGT, SGOT, bilirubin, and LDH levels. IM is usually a benign and self-limited disease. Complications including splenomegaly and splenic rupture, hepatitis, pericarditis, myocarditis, or central nervous system involvement (Guillain-Barre syndrome, Bell's palsy, transverse myelitis, and meningoencephalitis) may occur following IM infection. (1)
Epidemiology
EBV occurs throughout the world and more than 90% of adults have antibodies to the virus. Most individuals acquire EBV early in life. Seroepidemiologic studies have indicated that 50% of children have antibodies to the virus by the time they are 5 years of age. No seasonality has been demonstrated. (1)
Incubation Period
The incubation period is 4–7 weeks. (1)
Transmission
EBV is poorly contagious. Transmission is via salivary contact, either through kissing or by exposure to contaminated eating implements. (1)
Reference
1. Wiedbrauk D, Johnston SLG. Manual of Clinical Virology, Raven Press, New York, NY, 1993.
CPT Codes
86663, 86664, 86665.
Contacts
Special Chemistry Laboratory – RO
248-551-8071
Name: Special Chemistry Laboratory – RO
Location:
Phone: 248-551-8071
Last Updated
10/23/2024
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.